| Name | Title | Contact Details |
|---|
InfoCurrent is a Washington, DC-based company in the Business Services sector.
ALC is a Princeton, NJ-based company in the Business Services sector.
GWI is a consumer research company based in London, United Kingdom, employing between 501 and 1,000 people. The company specializes in providing global, on-demand insights that help businesses better understand their target audiences. GWIs flagship study encompasses over 2 billion people across 53 countries, offering valuable insights into consumer behaviors, attitudes, and perceptions. The company offers a variety of market research services, including brand tracking, audience profiling, market segmentation, and customer journey mapping. GWI also provides usage and attitude studies, concept development and testing, and ad effectiveness analysis. Its primary product is an on-demand consumer research platform that enables businesses to create charts, audiences, dashboards, and crosstabs for effective data analysis. GWI collaborates with notable clients such as Twitter, Google, Spotify, WPP, IPG, and Omnicom Group, showcasing its expertise in delivering actionable insights.
Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places.
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.